Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 15 versus DEXTROAMPHETAMINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 15 versus DEXTROAMPHETAMINE SULFATE.
ADDERALL 15 vs DEXTROAMPHETAMINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 15 is a combination of amphetamine and dextroamphetamine, which increase synaptic concentrations of norepinephrine and dopamine by inhibiting their reuptake and promoting their release from presynaptic terminals.
Increases extracellular levels of norepinephrine and dopamine by blocking reuptake and promoting release from presynaptic terminals, via trace amine-associated receptor 1 (TAAR1) agonism and vesicular monoamine transporter 2 (VMAT2) inhibition.
10-20 mg orally once daily in the morning; may increase by 5-10 mg weekly; maximum 40 mg/day.
5-60 mg/day orally divided every 4-6 hours, starting at 5 mg once or twice daily.
None Documented
None Documented
Mean terminal half-life: d-amphetamine 10 h, l-amphetamine 13 h (range 9-14 h); for ADDERALL 15 (3:1 mix), effective half-life ~11 h; clinical context: dosing interval typically QD-BID.
9-11 hours (adults); clinical context: twice-daily dosing achieves steady-state in ~2-3 days.
Primarily renal (90% as unchanged drug and metabolites; ~30% unchanged, 40% as 4-hydroxyamphetamine and conjugates, 20% as other metabolites); minimal biliary/fecal elimination (<3%).
Primarily renal (30-50% unchanged at acidic pH, less at alkaline pH); ~50% as metabolites (mostly deaminated and hydroxylated); minimal biliary/fecal.
Category C
Category D/X
CNS Stimulant
CNS Stimulant